Trial Profile
Retrospective study of aflibercept in Age-related macular degeneration patients non-responsive to bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 28 Nov 2015 New trial record